 |
|
|
| |
Response-guided danoprevir (DNV; RG7227) plus Peg-IFNα-2a and ribavirin (RBV) in ATLAS: High sustained virological response (SVR24) rates in treatment -naive hepatitis C virus (HCV) genotype 1 (G1) patients
|
| |
| |
Reported by jules Levin
Presented at the 22nd Conference of the Asian Pacific Association for the Study of the Liver (APASL 2012)
February 16-19, Taipei, Taiwan
Patrick Marcellin,1 Curtis Cooper,2 Luis A. Balart,3 Dominique G. Larrey,4 Terry D. Box,5 Eric Yoshida,6 Eric Lawitz,7 Peter Buggisch,8 Peter Ferenci,9 Martin Weltman,10 Emily Labriola-Tompkins,11 Sophie Le Pogam,11 Isabel Najera,11 Denise Thomas,11 Greg Hooper,12 Nancy Shulman,13 Ying Zhang,13 Mercidita T. Navarro,13 Chin Yin Lim,13 Michael Brunda,11 Ellen S. Yetzer,13 Norah Terrault14 on behalf of the ATLAS investigators
1Hopital Beaujon, Clichy, France; 2The Ottawa Hospital, Division of Infectious Diseases, Ottawa, ON, Canada; 3Tulane University Health Sciences Center, New Orleans, LA, United States; 4Montpellier School of Medicine, Montpellier, France; 5University of Utah Health Sciences Center, Salt Lake City, UT, United States; 6University of British Columbia, Vancouver, BC, Canada; 7Alamo Medical Research, San Antonio, TX, United States; 8IFI, Asklepiosklinik St. Georg, Hamburg, Germany; 9Medical University of Vienna, Vienna,
Austria; 10Nepean Hospital, Penrith, NSW, Australia; 11Roche, Nutley, NJ, United States; 12Roche, Welwyn, United Kingdom; 13Genentech, South San Francisco, CA, United States; 14University of California San Francisco, CA, United States
|
| |
|
|
|
|
|
